Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,898 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.
Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M; International Liver Disease Genetics Consortium. Thabet K, et al. Among authors: cheng w. Nat Commun. 2016 Sep 15;7:12757. doi: 10.1038/ncomms12757. Nat Commun. 2016. PMID: 27630043 Free PMC article.
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.
Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Günthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S. Rauch A, et al. Among authors: cheng w. Hepatology. 2009 Oct;50(4):1017-29. doi: 10.1002/hep.23101. Hepatology. 2009. PMID: 19670417
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group. Roberts SK, et al. Among authors: cheng ws. Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130. Hepatology. 2009. PMID: 19676125 Clinical Trial.
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; CHARIOT Study Group. Sievert W, et al. Among authors: cheng w. Hepatology. 2011 Apr;53(4):1109-17. doi: 10.1002/hep.24180. Hepatology. 2011. PMID: 21480317 Clinical Trial.
Comparison of noninvasive models of fibrosis in chronic hepatitis B.
Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, Bulsara M, Speers DJ, MacQuillan G, Ching HL, Kontorinis N, Cheng W, Flexman J, Fermoyle S, Rigby P, Walsh L, McLeod D, Adams LA. Raftopoulos SC, et al. Among authors: cheng w. Hepatol Int. 2012 Apr;6(2):457-67. doi: 10.1007/s12072-011-9296-5. Epub 2011 Jul 12. Hepatol Int. 2012. PMID: 21748376
8,898 results